Calley Means questions the vaccine's safety and effectiveness, but a clinical trial involving more than 40,000 people found stronger protection against influenza than a standard flu shot, with no clear serious safety signal.
WASHINGTON | A former adviser to the Trump administration's Department of Health and Human Services is challenging the safety and effectiveness of Moderna's newly approved messenger RNA influenza vaccine, despite clinical trial findings showing that the shot provided greater protection against seasonal flu than a conventional vaccine without identifying a clear serious safety problem.
Calley Means, a prominent figure in the Make America Healthy Again movement and former HHS adviser, made the claims during appearances on Joe Rogan's podcast and CBS News' "Face the Nation" earlier this month.
His comments have intensified scrutiny of the new vaccine, which received Food and Drug Administration approval in August for adults 50 and older.
The controversy comes as Americans enter another influenza season and public health officials confront persistent questions about vaccine safety, government oversight and the role of newer vaccine technologies.
At the center of the dispute is a fundamental distinction between what clinical trials demonstrate and how their findings are communicated to the public.
The available evidence indicates that Moderna's mRNA flu vaccine reduced laboratory-confirmed influenza cases more effectively than a standard-dose flu vaccine. Researchers also found higher rates of temporary reactions, including injection-site pain, fatigue and headaches, but no established increase in serious adverse events.
Clinical trial involving 40,703 participants found improved flu protection
Moderna's influenza vaccine was evaluated in a large randomized controlled clinical trial involving 40,703 participants.
Researchers compared the mRNA vaccine with an existing standard-dose influenza vaccine, rather than with a placebo.
The results indicated that participants receiving Moderna's vaccine experienced approximately 27% fewer laboratory-confirmed influenza illnesses than those receiving the conventional shot.
About 2% of participants in the mRNA vaccine group developed laboratory-confirmed flu, compared with approximately 2.8% in the standard-vaccine group.
The difference amounts to an absolute risk reduction of roughly 0.8 percentage points.
That figure has become central to Means' criticism.
During his Nov. 6 appearance on Rogan's podcast, Means characterized the benefit as nearly negligible and argued that the vaccine did not work.
But infectious disease specialists say that interpretation omits essential context: The comparison involved two active vaccines, not vaccinated and unvaccinated populations.
Standard influenza vaccines already reduce the likelihood of illness. Moderna's vaccine demonstrated an additional benefit beyond that existing protection.
Dr. CΓ©line Gounder, an infectious disease specialist and epidemiologist affiliated with KFF Health News, explained in comments provided to fact-checkers that the absolute difference should be understood in the context of an active vaccine comparison.
Put another way, the findings suggest that Moderna's vaccine prevented approximately one additional laboratory-confirmed influenza case for every 125 people vaccinated instead of receiving the standard-dose shot, under the conditions of the trial.
That estimate does not establish the vaccine's absolute effectiveness compared with receiving no vaccine.
For public health researchers, even relatively small improvements in influenza protection can be consequential when applied across large populations, although the ultimate effect depends on vaccine uptake, circulating flu strains and disease severity.
Means suggests vaccine deaths despite FDA findings
Means also raised concerns about deaths recorded during Moderna's clinical trials.
On Rogan's podcast, he described the vaccine as producing significant side effects and pointed to deaths among study participants, while acknowledging that a causal relationship had not been established.
In a Nov. 8 interview on CBS News' "Face the Nation," Means again referred to deaths in the clinical trial and questioned the FDA's handling of the application.
The clinical trial results, however, do not establish that the vaccine caused those deaths.
According to the published findings, approximately 0.2% of participants in each trial group died during follow-up, and investigators did not attribute those deaths to vaccination.
Deaths can occur during large clinical studies, particularly among older adults and participants with underlying medical conditions, for reasons unrelated to the intervention being tested.
FDA reviewers subsequently examined pooled safety information from multiple studies involving more than 70,000 participants.
Overall rates of serious adverse events and deaths were similar between the mRNA and standard-vaccine groups.
Reviewers did identify an imbalance in deaths classified as having unspecified causes: 23 among mRNA vaccine recipients compared with nine among standard-vaccine recipients.
That observation warranted examination, but it did not establish causation.
The FDA noted that these deaths occurred a median of 131 days after vaccination, without a clear clustering in timing. Reviewers considered the absence of an overall mortality imbalance and the underlying health conditions of participants.
Based on the available information, the agency concluded that the unspecified deaths were unlikely to represent a vaccine-related safety signal.
Moderna has committed to additional monitoring for certain serious outcomes.
The distinction is important: A death occurring after vaccination does not, by itself, demonstrate that vaccination caused the death.
Common side effects were more frequent with the mRNA vaccine
Although clinical trials did not establish a serious safety problem, Moderna's vaccine produced more short-term reactions than the conventional flu shot.
These symptoms generally reflect the body's response following vaccination and are distinct from serious adverse events.
Dr. William Schaffner, an infectious disease professor at Vanderbilt University Medical Center, said patients considering the mRNA vaccine should be informed that they may experience greater arm soreness, tenderness, mild fever or temporary fatigue.
Dr. Margot Savoy, chief medical officer of the American Academy of Family Physicians, similarly characterized the increased short-term symptoms as a consideration to discuss with patients.
The findings do not mean that every potential rare adverse effect has been excluded.
Clinical trials involving tens of thousands of participants can identify many common and uncommon problems but generally cannot rule out extremely rare complications.
Continued post-approval safety surveillance remains an essential component of vaccine oversight.
FDA approval followed dispute over clinical trial design
Moderna's approval process also became the subject of disagreement within the federal government.
In February, Dr. Vinay Prasad, then a senior FDA official overseeing vaccine regulation, initially prevented the agency from reviewing Moderna's application, according to reporting by STAT.
His objection centered on the clinical trial's comparison group.
Moderna had tested its vaccine against a standard-dose influenza shot rather than one of the enhanced vaccines recommended preferentially for adults 65 and older.
That distinction matters because older adults frequently have weaker immune responses and face a greater risk of severe influenza complications.
Enhanced vaccines, including high-dose and adjuvanted formulations, are intended to improve protection in that population.
However, Moderna sought authorization for adults beginning at age 50, and standard-dose influenza vaccines remain an established option for adults ages 50 to 64.
The FDA had also previously accepted the company's clinical development plans.
According to the supplied reporting, Prasad later reversed the initial decision following objections from Moderna and reports of White House involvement. The White House denied intervening.
Once the review proceeded, FDA staff and an independent advisory committee evaluated the evidence.
The committee unanimously concluded that the vaccine's benefits outweighed its risks.
The committee's role was advisory; final approval authority remained with the FDA.
Why approval differs for adults 50 to 64 and those 65 and older
The FDA's authorization reflected differences in the available evidence for two age groups.
For adults 65 and older, Moderna studied immune responses in approximately 3,000 participants who received either its mRNA vaccine or high-dose Fluzone.
The mRNA vaccine generated stronger measured immune responses in that comparison.
However, higher antibody responses do not automatically establish superior protection against laboratory-confirmed influenza, hospitalization or death.
Additional clinical evidence is expected in 2030.
Under the FDA's accelerated approval framework, continued authorization can depend on whether subsequent research confirms the anticipated clinical benefit.
Medical experts disagree over its place among preferred vaccines for seniors
The American Academy of Family Physicians has endorsed Moderna's mRNA vaccine as an age-appropriate influenza vaccination option for adults 50 and older.
For adults 65 and older, the organization includes the new shot among preferred options.
Nevertheless, some infectious disease specialists believe more direct clinical comparisons are needed before treating the mRNA vaccine as equivalent to established enhanced influenza vaccines.
Dr. Paul E. Sax, an infectious disease specialist at Brigham and Women's Hospital and Harvard Medical School, has expressed a preference for existing enhanced vaccines in older adults until further clinical evidence demonstrates that Moderna's stronger immune response produces meaningful additional protection.
Schaffner has also questioned whether the available evidence would be sufficient to place the new vaccine among preferred options for older adults.
These reservations do not establish that the vaccine is ineffective or unsafe.
Rather, they reflect uncertainty about its comparative effectiveness against enhanced products already recommended for seniors.
The distinction is particularly important for patients making vaccination decisions with their physicians.
mRNA technology could help accelerate future influenza vaccine development
Beyond seasonal influenza, the approval represents a potential milestone for vaccine manufacturing.
Messenger RNA technology uses genetic instructions that enable cells to produce a viral protein, prompting an immune response.
Unlike some conventional vaccine manufacturing processes, mRNA platforms can be redesigned relatively quickly when viral targets change.
That capability could prove valuable during a future influenza pandemic, when rapid vaccine development and manufacturing would be critical.
The technology does not eliminate the need for clinical testing, regulatory oversight or continued safety monitoring.
It does, however, offer another approach to addressing a virus that evolves continuously and contributes to substantial illness, hospitalization and death each year.
Vaccine oversight faces renewed political scrutiny
The debate over Moderna's flu vaccine is unfolding amid broader changes in federal vaccine policy under Health and Human Services Secretary Robert F. Kennedy Jr.
In June 2025, Kennedy replaced the membership of the Centers for Disease Control and Prevention's vaccine advisory committee.
The restructuring generated objections from medical organizations and vaccine researchers who questioned the committee's composition and subsequent recommendations.
According to the supplied reporting, a federal judge later temporarily blocked certain committee changes after finding procedural problems with its formation.
Medical organizations have consequently taken a more prominent role in communicating vaccination recommendations to clinicians and patients.
The broader dispute illustrates how regulatory decisions, clinical evidence and political messaging increasingly intersect in discussions about public health.
What patients should understand about the new flu vaccine
The evidence available from Moderna's clinical trials supports several conclusions.
The vaccine provided better protection against laboratory-confirmed influenza than the standard-dose vaccine used in the principal trial.
Temporary side effects were more common, but serious adverse-event rates were similar between groups, and investigators did not establish that the vaccine caused the deaths observed during the studies.
Important questions remain about how its protection compares with enhanced influenza vaccines in adults 65 and older and whether rare adverse effects will emerge during wider use.
Those uncertainties are reasons for continued research and monitoring, not evidence that the vaccine has been demonstrated to cause fatal harm.
Patients should consider their age, medical history, available vaccine options and guidance from qualified health professionals when deciding which influenza vaccine to receive.
The bottom line
Calley Means' public comments emphasize the small absolute difference in influenza cases, the greater frequency of temporary side effects and deaths recorded during clinical trials.
Those observations require context.
The trial compared Moderna's vaccine with an existing flu vaccine that already provides protection. The additional reduction in influenza cases was statistically and clinically relevant to the comparison, even though the absolute difference was less than one percentage point.
And although deaths occurred among trial participants, the FDA's review did not establish that the vaccine caused them.
The remaining questions about comparative effectiveness in older adults and very rare safety risks deserve continued examination.
The central finding is that the available clinical evidence supports Moderna's mRNA influenza vaccine as an effective option for eligible adults, while additional research is needed to establish its longer-term safety profile and relative benefits against enhanced flu vaccines.




No comments:
Post a Comment